Pertuzumab
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Pertuzumab
- Pertuzumab: From HER2-Positive Breast Carcinoma to Progesterone-Receptor Positive Breast Cancer
Pertuzumab: From HER2-Positive Breast Carcinoma to Progesterone-Receptor Positive Breast Cancer
One-Sentence Summary
Pertuzumab is a HER2-targeted monoclonal antibody, originally used to treat HER2-positive breast carcinoma. The TxGNN model predicts it may be effective for progesterone-receptor positive breast cancer, which is essentially the hormone-receptor-positive subgroup of HER2-positive disease. Currently 1 clinical trial and 20 publications support this direction, including several randomized trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-positive breast carcinoma |
| Predicted New Indication | Progesterone-receptor positive breast cancer |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L1 |
| US Market Status | Cancelled only (the single BLA is listed as cancelled) |
| Number of NDAs | 1 (BLA) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Pertuzumab binds the extracellular dimerization domain (subdomain II) of HER2 and blocks HER2-HER3 heterodimerization. This suppresses the downstream PI3K/AKT and MAPK signaling pathways. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description is based on general knowledge of pertuzumab.
HER2-positive tumors can also express progesterone receptor (the HR+/HER2+ subtype). In these tumors, HER2 remains a key driver, so the same mechanism applies. The prediction is therefore best understood as an extension of the approved HER2-positive indication into a hormone-receptor subgroup, not a new target.
Two caveats are worth noting. First, many pivotal studies enrolled HER2-positive patients regardless of hormone-receptor status, so PR-specific results are often found only in subgroup analyses. Second, crosstalk between HER2 and hormone-receptor signaling may influence response, which is why trials combining dual HER2 blockade with endocrine therapy are of particular interest.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04629846 | Phase 3 | Completed | 517 | Randomized, double-blind equivalence trial of pertuzumab biosimilar QL1209 vs. reference pertuzumab, each with trastuzumab and docetaxel, in neoadjuvant HER2-positive, ER/PR-negative breast cancer |
Note: this is a biosimilar equivalence trial in a hormone-receptor-negative population. It supports the efficacy of the pertuzumab regimen overall but does not by itself establish efficacy in PR-positive disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27179402 | 2016 | RCT (Phase 2) | Lancet Oncol | NeoSphere 5-year analysis: neoadjuvant pertuzumab + trastuzumab + docetaxel in HER2-positive breast cancer; progression-free and disease-free survival and safety |
| 28945833 | 2017 | RCT (Phase 2) | Ann Oncol | WSG-ADAPT HER2+/HR-: 12 weeks of neoadjuvant trastuzumab + pertuzumab with or without weekly paclitaxel |
| 38906970 | 2024 | RCT (Phase 3) | Br J Cancer | QL1209 pertuzumab biosimilar equivalence trial in HER2-positive, ER/PR-negative breast cancer |
| 42150145 | 2026 | RCT | J Clin Oncol | WSG TP-II survival analysis: neoadjuvant trastuzumab + pertuzumab + endocrine therapy vs. chemotherapy in HR+/HER2+ early breast cancer |
| 37166817 | 2023 | RCT | JAMA Oncol | WSG-TP-II: endocrine therapy plus dual HER2 blockade vs. de-escalated chemotherapy in HR+/HER2+ early breast cancer |
| 36716289 | 2023 | Trial (final analysis) | Clin Cancer Res | PERTAIN: adding pertuzumab to trastuzumab and an aromatase inhibitor in HER2+/HR+ metastatic or locally advanced breast cancer (more than 6 years’ follow-up) |
| 35640077 | 2022 | Guideline | J Clin Oncol | ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer |
| 42061014 | 2026 | Cohort | Cancer Treat Res Commun | Real-world data from India on the pertuzumab-docetaxel-trastuzumab regimen in HER2-positive metastatic breast cancer |
| 27057657 | 2016 | Review | Cancer Treat Rev | Overview of HR+/HER2+ breast cancer, including HER2-hormone receptor crosstalk |
| 40983817 | 2025 | Review | Breast Cancer | Signaling pathway interactions and clinical translation in HR+/HER2+ breast cancer |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125409 (status: cancelled) | PERJETA (Genentech, Inc.) | Injection, solution, concentrate | Not listed in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-HER2 monoclonal antibody), not a conventional cytotoxic |
| Myelosuppression Risk | Low as a single agent; myelosuppression in regimens is mainly from the combined chemotherapy (e.g., docetaxel) |
| Emetogenicity Classification | Low |
| Monitoring Items | Please refer to the package insert warnings and precautions; cardiac function monitoring is generally relevant for anti-HER2 regimens (cardiac safety studies such as TRYPHAENA and BERENICE are in the literature) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: A moderate-level interaction with idelalisib was recorded. The other interaction entry reflects pertuzumab’s pharmacological target (HER2/ERBB2) rather than a drug-drug interaction.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several randomized trials, including the completed Phase 3 trial, the WSG-TP-II trial and the PERTAIN trial, support pertuzumab-based regimens across HER2-positive disease, including HR+/HER2+ tumors. However, the prediction is largely an extension within the already approved HER2-positive indication, and the only registered trial in the data focuses on the ER/PR-negative population. In addition, the US license is listed as cancelled.
To proceed, the following is needed:
- PR-status-specific subgroup efficacy data (e.g., from NeoSphere, PERTAIN and WSG-TP-II)
- Package insert warnings and contraindications (not available in the compiled data)
- Detailed mechanism-of-action data from DrugBank
- Clarification of current US regulatory and supply status
- A cardiac safety monitoring plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.